- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03371979
Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00927
- Fundacion De Investigacion, Hematology/Oncology
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36604
- University of Alabama, Mitchell Cancer Institute
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
Denver, Colorado, United States, 80218
- Rocky Mountain Cancer Centers
-
-
Florida
-
Orange City, Florida, United States, 32763
- Mid Florida Hematology and Oncology Centers
-
Pensacola, Florida, United States, 32503
- Woodlands Medical Specialists, PA
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30307
- Emory University
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Nebraska Cancer Specialists
-
-
New Jersey
-
Paramus, New Jersey, United States, 07652
- The Valley Hospital, Luckow Pavilion
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- Oncology Hematology Care Inc.
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- UPMC Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414
- Charleston Hematology Oncology Associates
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- West Clinic
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
Houston, Texas, United States, 77024
- Texas Oncology-Memorial City
-
Tyler, Texas, United States, 75702
- Texas Oncology-Tyler
-
-
Virginia
-
Blacksburg, Virginia, United States, 24060
- Oncology & Hematology Associates of SW Virginia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Patient is able and willing to provide written informed consent
- Be > 18 years of age on day of signing informed consent
Have histologically or cytologically confirmed SCLC that meets:
- Extensive disease per criteria of the International Association for the Study of Lung Cancer (IASLC)-American Joint Committee on Cancer (AJCC) TNM staging system
- Have not tolerated or have progressed or relapsed on or within 6 months of platinum-based chemotherapy
- Have a performance status of ≤ 1 on the ECOG Performance Scale
- Have measurable disease based on RECIST 1.1
- Willing to undergo core needle or incisional biopsy to obtain fresh tumor tissue specimens
- Demonstrate adequate organ function as evidenced by laboratory testing with specimens collected within 10 days prior to day 1 of cycle 1
- Female child-bearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication
- Sexually active male or female must be surgically sterile post-menopausal, or must agree to use a physician-approved method of birth control during the study through a minimum of 120 days after the last study drug administration.
Key Exclusion Criteria:
- Has received more than 2 platinum-based regimens against SCLC
- Has received pembrolizumab, or prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody as part of any previous therapy, including trials
- Has participated in Merck MK-3475 (pembrolizumab) clinical trials
- Has received pegzilarginase as part of any previous therapy
- Is currently participating in a study of an investigational agent or received the last dose of an investigational agent within 4 weeks prior to the first dose of treatment in this study (a shorter interval for kinase inhibitors or other short half-life drugs could be considered after approval from the Sponsor). Is currently participating in a study of an investigational device within 4 weeks of the first dose of treatment
- Has a diagnosis of an immunodeficiency, is receiving systemic steroid therapy (except for physiological dose levels), or immunosuppressive therapies
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer) that has undergone potentially curative therapy
- Has known central nervous system (CNS) metastases. However, patients with previously treated brain metastases may participate provided neurologic symptoms have stabilized, there is no evidence of new brain metastases or hemorrhage and they are not using steroids for brain metastases or for complications derived from their treatment for at least 7 days prior to the first dose of trial treatment
- Has known carcinomatous meningitis
- Has an active autoimmune disease requiring systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs) or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy are an exception to this rule. Patients that require intermittent use of bronchodilators or local steroid injections will not be excluded from the study. Patients with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a form of systemic treatment
- Has evidence of interstitial lung disease, history of non-infectious pneumonitis that required steroids, or current pneumonitis
- Inadequately controlled hypertension (defined as systolic blood pressure ≥ 200 mmHg and/or diastolic blood pressure ≥ 120 mmHg) on more than one occasion in the month before planned day of infusion
- Currently taking 3 or more anti-hypertensive medications
- Prior history of hypertensive crisis or hypertensive encephalopathy
- History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or cardiac or vascular surgery within 6 months prior to day 1 of study treatment
- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
- Has a known history of Human Immunodeficiency Virus (HIV) (positive for HIV p24 antigen or HIV 1/2 antibodies)
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected)
- Has a known history of active tuberculosis (Bacillus tuberculosis)
- Has had an allogenic tissue/solid organ transplant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pegzilarginase plus Pembrolizumab
Phase 1 & 2
|
Administered IV
Other Names:
Administered IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1. Phase 1: Incidence of treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: Estimated up to 6 months
|
1. Number of participants experiencing treatment-related adverse events as assessed by CTCAE v4.0.
|
Estimated up to 6 months
|
Phase 2: Efficacy determined by Objective Response Rate (ORR:CR+PR) per RECIST 1.1.
Time Frame: Estimated up to 6 months
|
1. Objective Response Rate (ORR:) per RECIST 1.1 • The Objective Response Rate (ORR) is defined as the percentage of subjects whose best objective response (BOR) is either complete response (CR) or partial response (PR). The ORR will be derived from the BOR according to response evaluation criteria in solid tumors (RECIST) v1.1 as assessed by the Investigator. |
Estimated up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate
Time Frame: At 9, 18, and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
|
Percentage of patients whose cancer achieves either complete response (CR) or partial response (PR).
|
At 9, 18, and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
|
Clinical Benefit Rate
Time Frame: At 18 and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
|
Percentage of patients who have achieved CR, PR or Stable Disease (SD), lasting at least 8 weeks.
|
At 18 and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
|
Time to Response
Time Frame: At 9, 18, and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
|
Time (weeks) from first treatment to the first documented CR or PR.
|
At 9, 18, and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
|
Duration of Response
Time Frame: At 18 and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
|
Time (weeks) from first documented CR or PR, until disease progression (PD).
|
At 18 and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
|
Progression free survival
Time Frame: From first treatment up to 24 months
|
Time (weeks) from first treatment to first observation of PD or death from any cause.
|
From first treatment up to 24 months
|
Overall Survival
Time Frame: From first treatment up to 24 months
|
Time (weeks) from first treatment to death due to any cause.
|
From first treatment up to 24 months
|
Phase 2: Incidence of treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: From first treatment up to 24 months
|
Number of participants experiencing treatment-related adverse events as assessed by CTCAE v4.0.
|
From first treatment up to 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAEB1102-101B; KEYNOTE PN758
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small-cell Lung Cancer
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
Washington University School of MedicineMerck Sharp & Dohme LLCWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small Cell Lung Extensive Stage
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedTobacco Use Disorder | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Peking Union Medical College HospitalRecruitingNon Small Cell Lung Cancer Stage III | Small-Cell Lung CancerChina
-
University of Maryland, BaltimoreUniversity of Maryland, College ParkTerminatedNon-Small Cell Lung Cancer, Small Cell Lung Cancer | Platinum Responsive MalignanciesUnited States
Clinical Trials on Pegzilarginase
-
Aeglea BiotherapeuticsTerminatedArginase I Deficiency | HyperargininemiaCanada
-
Aeglea BiotherapeuticsCompletedArginase I Deficiency | HyperargininemiaUnited States, Canada, United Kingdom, Portugal
-
Aeglea BiotherapeuticsCompletedArginase I Deficiency | HyperargininemiaUnited States, Italy, Canada, France, United Kingdom, Austria, Germany